Quantitative determination of Asenapine in both bulk and formulations using neutralization titrations

Aarelly, Kiran; Thimmaraju, Manish Kumar; Nerella, Raghunandan
August 2012
Journal of Applied Pharmaceutical Science;Aug2012, Vol. 2 Issue 8, p141
Academic Journal
Asenapine is used in the treatment of schizophrenia disease. Asenapine mainly control the psychotic symptoms' mainly antagonist to various receptors like, serotonin (5-HT1A, 5- HT1B,5-HT2A,5-HT2B,),histamine, and dopamine(D1,D2,D3,D4) receptors. It is also lower affinity towards muscaranic and acetylcholine receptors. In the present study, simple titrimetric method was developed. Respective quantities of Asenapine were taken in aqueous methanol titrated against 0.1N sodium hydroxide acid and 0.1N potassium hydroxide acid using phenolphthalein as an indicators for neutralization titration. This method were found to be sensitive and inexpensive, do not require any sample processing steps and can be utilized for estimation of asenapine in bulk and formulations.


Related Articles

  • Determination of Furan Levels in Coffee Using Automated Solid-Phase Microextraction and Gas Chromatography/Mass Spectrometry. I-Pin Ho; Seong-Jae Yoo; Tefera, Sebhat // Journal of AOAC International;Mar/Apr2005, Vol. 88 Issue 2, p574 

    Describes an analytical method for furan analysis using an automated solid-phase microextraction system in combination with gas chromatography/mass spectroscopy. Performance of the method; Results obtained from a variety of coffee; Detection limit of furan.

  • Editorial. Takano, Akihiro // Current Pharmaceutical Design;1/21/2010, Vol. 16 Issue 3, p308 

    The article highlights the author's views on the treatment of schizophrenia. It defines schizophrenia as a psychiatric disorder characterized with delusions, lack of emotion and cognitive dysfunction. The therapeutic targets of antipsychotics in patients with schizophrenia are cited. The author...

  • Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Acheson, Dean T.; Twamley, Elizabeth W.; Young, Jared W. // Frontiers in Neuroscience;Jun2013, Vol. 7, p1 

    Rationale: Impaired cognitive abilities are a key characteristic of schizophrenia. Although currently approved pharmacological treatments have demonstrated efficacy for positive symptoms, to date no pharmacological treatments successfully reverse cognitive dysfunction in these patients....

  • α7 and β2 Nicotinic Acetylcholine Receptor Subunits Form Heteromeric Receptor Complexes that Are Expressed in the Human Cortex and Display Distinct Pharmacological Properties. Thomsen, Morten Skøtt; Zwart, Ruud; Ursu, Daniel; Jensen, Majbrit Myrup; Pinborg, Lars Hageman; Gilmour, Gary; Wu, Jie; Sher, Emanuele; Mikkelsen, Jens Damsgaard // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    The existence of α7β2 nicotinic acetylcholine receptors (nAChRs) has recently been demonstrated in both the rodent and human brain. Since α7-containing nAChRs are promising drug targets for schizophrenia and Alzheimer’s disease, it is critical to determine whether α7β2...

  • Development and Validation of HPTLC Method for Estimation of Tenoxicam and its Formulations. CHANDEL, S.; BARHATE, C. R.; SRIVASTAVA, A. R.; KULKARNI, S. K.; KAPADIA, C. J. // Indian Journal of Pharmaceutical Sciences;Jan/Feb2012, Vol. 74 Issue 1, p36 

    A simple, precise, accurate and rapid high performance thin layer chromatographic method has been developed and validated for the estimation of tenoxicam in the microemulsion gels. Tenoxicam was chromatographed on silica gel 60 F254 TLC plate, as a stationary phase. The mobile phase was toluene:...

  • Clozapine/lorazepam withdrawal.  // Reactions Weekly;3/16/2013, Issue 1444, p15 

    The article presents a case study of a 39 year old woman who developed psychosis and catatonia while being treated for schizophrenia from last eight years.

  • Attenuated Psychosis Syndrome. Reddy, M. S. // Indian Journal of Psychological Medicine;Jan-Mar2014, Vol. 36 Issue 1, p1 

    An introduction is presented in which the editor discusses various reports within the issue on topics including attenuated psychosis syndrome (APS), the treatment of schizophrenia, and duration of untreated psychosis (DUP).

  • Schizophrenia Advances. Holman, Virginia // Self;Nov98, Vol. 20 Issue 11, p96 

    Deals with the class of drugs for schizophrenia, a chemical brain disorder. Antipsychotic drugs for the disorder; Side effects of the antipsychotic drugs; Effectiveness of the drugs.

  • Gabapentin-Induced Paradoxical Exacerbation of Psychosis in a Patient With Schizophrenia.  // Canadian Journal of Psychiatry;Dec2002, Vol. 47 Issue 10, p975 

    Focuses on the role of anticonvulsant, gabapentin, induced by paradoxical exacerbation of psychosis in a patient with schizophrenia. Effects of gabapentin on patients; Psychotic symptoms of the disease; Mechanisms to explain the effect of gabapentin on patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics